StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3051% below fair value
$3.82−0.31 (-7.51%)

Close on Nov 16, 2026Market cap $120.03MP/E –Yield –

LENZ Therapeutics total assets

Total assets on the balance sheet at the end of each period.

LENZ Therapeutics's total assets was $236.60M at Jun 30, 2026. For fiscal 2025 it was $305.88M, up 42.1% from the year before. The highest annual figure on record is $401.99M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$305.88M+42.1%
FY2024Dec 31, 2024$215.30M+205.9%
FY2023Dec 31, 2023$70.38M-78.1%
FY2022Dec 31, 2022$321.90M-19.9%
FY2021Dec 31, 2021$401.99M+1681.5%
FY2020Dec 31, 2020$22.56M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$236.60M+8.9%
Q1 FY2026Mar 31, 2026$272.54M+35.4%
Q4 FY2025Dec 31, 2025$305.88M+42.1%
Q3 FY2025Sep 30, 2025$210.70M-5.9%
Q2 FY2025Jun 30, 2025$217.33M+7.3%
Q1 FY2025Mar 31, 2025$201.25M-7.4%
Q4 FY2024Dec 31, 2024$215.30M+205.9%
Q3 FY2024Sep 30, 2024$224.01M-15.9%
Q2 FY2024Jun 30, 2024$202.64M-29.4%
Q1 FY2024Mar 31, 2024$217.32M-29.9%
Q4 FY2023Dec 31, 2023$70.38M-78.1%
Q3 FY2023Sep 30, 2023$266.23M-20.5%
Q2 FY2023Jun 30, 2023$287.04M-18.9%
Q1 FY2023Mar 31, 2023$310.00M-18.1%
Q4 FY2022Dec 31, 2022$321.90M-19.9%
Q3 FY2022Sep 30, 2022$334.85M-19.5%
Q2 FY2022Jun 30, 2022$353.79M-8.6%
Q1 FY2022Mar 31, 2022$378.61M+1577.9%
Q4 FY2021Dec 31, 2021$401.99M–
Q3 FY2021Sep 30, 2021$416.15M–
Q2 FY2021Jun 30, 2021$387.11M–
Q4 FY2020Dec 31, 2020$22.56M–

More LENZ Therapeutics figures

See a number that looks wrong?